{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:45:59Z","timestamp":1793123159601,"version":"4.5.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186120","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T13:54:49Z","timestamp":1507211689000},"page":"e0186120","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients"],"prefix":"10.1371","volume":"12","author":[{"given":"Ji Young","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-5366","authenticated-orcid":true,"given":"Seong-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Youn","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sun","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Hee","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Mo","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Kyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Nam","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"JA Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"Supplement 3","key":"ref2","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5","author":"P Sensi","year":"1983","journal-title":"Review of Infectious Diseases"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002280050426","article-title":"Rifaximin systemic absorption in patients with ulcerative colitis","volume":"54","author":"F Rizzello","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"ref4","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"14","author":"JJ Descombe","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"issue":"Suppl 1","key":"ref5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"C Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","article-title":"Rifaximin: a review of its use in the management of traveller&apos;s diarrhoea","volume":"65","author":"GW Robins","year":"2005","journal-title":"Drugs"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2007.03259.x","article-title":"High dosage rifaximin for the treatment of small intestinal bacterial overgrowth","volume":"25","author":"E Scarpellini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1586\/17474124.2016.1140571","article-title":"Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome","volume":"10","author":"JS Kane","year":"2016","journal-title":"Expert review of gastroenterology & hepatology"},{"issue":"1","key":"ref9","first-page":"83","article-title":"Rifampicin\u2014an overview","volume":"3","author":"F Rana","year":"2013","journal-title":"Int J Res Pharm Chem"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jinf.2010.11.004","article-title":"Rifaximin intake leads to emergence of rifampin-resistant staphylococci","volume":"62","author":"T Valentin","year":"2011","journal-title":"J Infect"},{"key":"ref11","article-title":"Repeat Treatment With Rifaximin is Safe and Effective in Patients With Diarrhea-predominant Irritable Bowel Syndrome","author":"A Lembo","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clinthera.2011.06.007","article-title":"Rifaximin: new therapeutic indication and future directions","volume":"33","author":"A Rivkin","year":"2011","journal-title":"Clin Ther"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"KD Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eucast.org\" xlink:type=\"simple\">http:\/\/www.eucast.org<\/ext-link>."},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/edm.10.6","article-title":"Staphylococcus colonization of the skin and antimicrobial peptides","volume":"5","author":"M Otto","year":"2010","journal-title":"Expert review of dermatology"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10096-016-2672-2","article-title":"Staphylococcus aureus colonization related to severity of hand eczema","volume":"35","author":"S Mernelius","year":"2016","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"995","key":"ref17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis","volume":"207","author":"C Calvori","year":"1965","journal-title":"Nature"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jinf.2004.05.019","article-title":"Rifaximin\u2014a novel antimicrobial for enteric infections","volume":"50","author":"DB Huang","year":"2005","journal-title":"J Infect"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1572-0241.2003.07283.x","article-title":"Therapy of travelers&apos; diarrhea with rifaximin on various continents","volume":"98","author":"R Steffen","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.43.11.2813","article-title":"Molecular Characterization of rpoBMutations Conferring Cross-Resistance to Rifamycins on Methicillin-Resistant Staphylococcus aureus","volume":"43","author":"TA Wichelhaus","year":"1999","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"DL Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/42.5.621","article-title":"Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis","volume":"42","author":"B Yang","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile","volume":"52","author":"JR O'Connor","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.02163-12","article-title":"Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-beta-naphthylamide-inhibitable efflux pumps","volume":"57","author":"V Kothary","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1469-0691.1997.tb00272.x","article-title":"Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin","volume":"3","author":"O Soro","year":"1997","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"ref26","first-page":"371","article-title":"Antimycobacterial activity of rifaximin (L\/105) in experimental tuberculosis in the guinea pig","volume":"3","author":"M Lucchesi","year":"1984","journal-title":"Chemioterapia"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance","volume":"58","author":"MS Kim","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"A Marchese","year":"2000","journal-title":"Chemotherapy"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/596315","article-title":"High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital","volume":"48","author":"SR Curry","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jinf.2014.04.003","article-title":"Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin","volume":"69","author":"T Valentin","year":"2014","journal-title":"Journal of Infection"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High Activity of Fosfomycin and Rifampin against Methicillin-Resistant Staphylococcus aureus Biofilm In Vitro and in an Experimental Foreign-Body Infection Model","volume":"58","author":"R Mihailescu","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"e114127","DOI":"10.1371\/journal.pone.0114127","article-title":"Clinical and epidemiological factors associated with methicillin resistance in community-onset invasive Staphylococcus aureus infections: prospective multicenter cross-sectional study in Korea","volume":"9","author":"ES Kim","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/jac\/dkr059","article-title":"Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples","volume":"66","author":"M Villar","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-2180-12-240","article-title":"Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China","volume":"12","author":"W Zhou","year":"2012","journal-title":"BMC Microbiol"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MCG.0b013e31827559a3","article-title":"Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?","volume":"47","author":"DJ Farrell","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/163.6.1279","article-title":"Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus","volume":"163","author":"HM Blumberg","year":"1991","journal-title":"J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T04:56:07Z","timestamp":1570164967000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186120"}},"subtitle":[],"editor":[{"given":"Karsten","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186120","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}